ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company publicly traded on the NASDAQ under the symbol ALXO. The company is focused on developing therapies that block the CD47 immune checkpoint inhibitor to help patients fight cancer. Their lead product candidate, evorpacept, is a next-generation CD47 blocker designed to have a high affinity for CD47 and avoid the limitations caused by hematologic toxicities. Evorpacept is currently in multiple Phase 1 and 2 clinical trials and has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with leading anti-cancer antibodies.

ALX Oncology is actively pursuing a strategy of combining evorpacept with various anti-cancer agents, including anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors. Their goal is to establish evorpacept as a critical component in future oncology combination treatments, leveraging the immune activation of broadly used anti-cancer agents to maximize clinical activity while minimizing toxicities.

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company committed to fighting cancer by developing novel therapies that block the CD47 immune checkpoint inhibitor. Their lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic designed to maximize clinical activity and minimize toxicities. ALX Oncology aims to bridge the innate and adaptive immune systems, enabling the body's natural defenses to effectively target and eliminate cancer cells. Their focus is on combining evorpacept with leading anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors to create potentially critical components of future oncology combination treatments.

ALX Oncology promotes a culture focused on developing innovative therapies to fight cancer. They emphasize a collaborative work environment, seeking exceptional candidates who are committed to helping patients. The company values a strong scientific foundation and a commitment to advancing the field of immuno-oncology through its research and clinical trials.